Maintenance with daratumumab or observation following treatment with bortezomib, thalidomide, and dexamethasone with or without daratumumab and autologous stem-cell transplant in patients with newly diagnosed multiple myeloma (CASSIOPEIA): an open-label, randomised, phase 3 trial-Reference-Cited by-同舟云学术

Maintenance with daratumumab or observation following treatment with bortezomib, thalidomide, and dexamethasone with or without daratumumab and autologous stem-cell transplant in patients with newly diagnosed multiple myeloma (CASSIOPEIA): an open-label, randomised, phase 3 trial

Published:2021-10 Issue:10 Volume:22 Page:1378-1390
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Moreau Philippe,Hulin Cyrille,Perrot Aurore,Arnulf Bertrand,Belhadj Karim,Benboubker Lotfi,Béné Marie C,Zweegman Sonja,Caillon Hélène,Caillot Denis,Corre Jill,Delforge Michel,Dejoie Thomas,Doyen Chantal,Facon Thierry,Sonntag Cécile,Fontan Jean,Mohty Mohamad,Jie Kon-Siong,Karlin Lionel,Kuhnowski Frédérique,Lambert Jérôme,Leleu Xavier,Macro Margaret,Orsini-Piocelle Frédérique,Roussel Murielle,Stoppa Anne-Marie,van de Donk Niels W C J,Wuillème Soraya,Broijl Annemiek,Touzeau Cyrille,Tiab Mourad,Marolleau Jean-Pierre,Meuleman Nathalie,Vekemans Marie-Christiane,Westerman Matthijs,Klein Saskia K,Levin Mark-David,Offner Fritz,Escoffre-Barbe Martine,Eveillard Jean-Richard,Garidi Réda,Ahmadi Tahamtan,Krevvata Maria,Zhang Ke,de Boer Carla,Vara Sanjay,Kampfenkel Tobias,Vanquickelberghe Veronique,Vermeulen Jessica,Avet-Loiseau Hervé,Sonneveld Pieter

Funder

Janssen Research and Development LLC

Publisher

Elsevier BV

Subject

Oncology

Reference23 articles.

1. Emerging therapies for the treatment of relapsed or refractory multiple myeloma;Dimopoulos;Eur J Haematol,2011

2. Clinical course of patients with relapsed multiple myeloma;Kumar;Mayo Clin Proc,2004

3. Multiple myeloma: patient outcomes in real-world practice;Yong;Br J Haematol,2016

4. European Myeloma Network recommendations on the evaluation and treatment of newly diagnosed patients with multiple myeloma;Engelhardt;Haematologica,2014

5. Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up;Dimopoulos;Ann Oncol,2021

Cited by 108 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Belantamab mafodotin, pomalidomide, and dexamethasone for triple class exposed/refractory relapsed multiple myeloma: a subgroup analysis of the ALGONQUIN trial;Blood Cancer Journal;2024-09-11

2. Efficacy of daratumumab on multiple myeloma patients with renal insufficiency: a systematic review and meta-analysis;Hematology;2024-09-09

3. Maintenance therapy for cytogenetically high-risk multiple myeloma: landscape in the era of novel drugs;Clinical and Experimental Medicine;2024-08-06

4. Impact of M‐protein detection on the response evaluations of patients undergoing treatment with the IgG‐κ monoclonal antibodies daratumumab or isatuximab, and discrepancies between immunofixation electrophoresis (IFE) systems and reagents;Cancer Medicine;2024-08

5. Bortezomib, thalidomide, and dexamethasone with or without daratumumab and followed by daratumumab maintenance or observation in transplant-eligible newly diagnosed multiple myeloma: long-term follow-up of the CASSIOPEIA randomised controlled phase 3 trial;The Lancet Oncology;2024-08